Eli Lilly said its experimental daily obesity pill helped patients maintain most of their weight loss after switching from injectable drugs like Zepbound. MAGA reacts to new video from deadly ...

The Phase 3 study showed that at 52 weeks, patients who switched to orforglipron from Wegovy maintained their weight loss with an average difference of 0.9 kg, while those who switched from Zepbound ...

Orforglipron maintains weight loss after switching from injectable GLP-1 drugs Lilly and Novo Nordisk await U.S. regulatory approvals for weight-loss pills FDA may expedite review of Lilly's ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split. Eli Lilly's shares look attractive ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the FDA for approval on Thursday. Eli Lilly’s LLY drug is called orforglipron.

Eli Lilly and Co. (NYSE: LLY) on Friday shared updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant) for previously treated breast cancer patients. The trial included patients with ...

Here's how the next generation of obesity drugs getting closer to patients differs from Wegovy and Zepbound Novo Nordisk (whose injectable weight-loss medication Wegovy is shown here) and rival Eli ...

Novo Nordisk NVO received Food and Drug Administration approval for its Wegovy pill as a treatment for obesity on Dec. 22. The company plans to launch the 25mg semaglutide pill in the United States in ...

Eli Lilly is positioned for a secular growth trajectory, leveraging its duopoly in diabetes and obesity therapies while investing heavily in pipeline diversification. LLY faces intensifying ...

FDA chief's office said it wants to cut the filing review from 60 days to one week The office said it may cut those reviews to two or three weeks based on complexity The agency could decide on Lilly's ...

Lily is leaving Young and Restless as portrayer Christel Khalil has begun her maternity leave to welcome her third child.